UBS Maintains Neutral on IDEXX Laboratories, Lowers Price Target to $620
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and lowers the price target from $640 to $620.
UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and lowers the price target from $640 to $620.